WaveMan
WaveMan · Company
MNPR · Monopar Therapeutics
> Search tickers & screens ⌘K
LIVE
← All companies

MNPR Monopar Therapeutics (MNPR) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001645469
Quote by TradingView
Form 144 · 5
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
64
13F, latest reported quarter
Conversions, 180 days
14
Codes C/M, not in net · $816.1K priced

What the filings say about MNPR

Insiders, 180 days
-$4.0M net sold
5 sellers · 100% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$5.5M
5 notices

Monopar Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Monopar Therapeutics insiders sold a net $4.0M of stock across 38 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
STARR CHRISTOPHER M
Director
SELL
2026-10-05 SECtraded 2026-10-01
4,631
$361.6K
-11.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 14, 2025.
  • The trade is 51.8% of the 8,942 shares held after it.
  • 1 other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director STARR CHRISTOPHER M sold about $361.6K of MNPR under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 64 funds added in the latest 13F quarter.
STARR CHRISTOPHER M
Director
SELL
2026-10-05 SECtraded 2026-10-01
2,970
$234.1K
-11.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 14, 2025.
  • The trade is 49.7% of the 5,972 shares held after it.
  • 1 other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director STARR CHRISTOPHER M sold about $234.1K of MNPR under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 64 funds added in the latest 13F quarter.
STARR CHRISTOPHER M
Director
SELL
2026-10-05 SECtraded 2026-10-01
799
$63.7K
-11.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 14, 2025.
  • The trade is 15.4% of the 5,173 shares held after it.
  • 1 other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director STARR CHRISTOPHER M sold about $63.7K of MNPR under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 64 funds added in the latest 13F quarter.
Robinson Chandler
Chief Executive Officer
SELL
2026-09-28 SECtraded 2026-09-24
10,450
$910.7K
-11.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 14, 2025.
  • The trade is 8.9% of the 117,873 shares held after it.
  • 4 other insiders sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Robinson Chandler sold about $910.7K of MNPR under a 10b5-1 plan on Sep 24, 2026, the largest insider sale at the company since 2025; 4 other insiders sold within 30 days and 64 funds added in the latest 13F quarter.
Robinson Chandler
Chief Executive Officer
SELL
2026-09-28 SECtraded 2026-09-24
9,638
$847.8K
-11.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 14, 2025.
  • The trade is 8.9% of the 108,235 shares held after it.
  • 4 other insiders sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Robinson Chandler sold about $847.8K of MNPR under a 10b5-1 plan on Sep 24, 2026, the largest insider sale at the company since 2025; 4 other insiders sold within 30 days and 64 funds added in the latest 13F quarter.
38 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 33 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$4.0M over 180 days
-$4.0M over 90 days
below 76% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
64 funds bought in last quarter
more than 53% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
$35.0M repurchased, FY to 2025-12-31
more than 50% of Pharma & Biotech
Short interest
24.3% of the float short (float per yahoo 2026-10-26) · 6.0 days to cover · settled 2026-09-30
more than 88% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 5Director STARR CHRISTOPHER M sold $659.4K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Director CHRISTOPHER STARR filed to sell $1.3M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch MNPR

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-13.2%12M
-38%-8%+22%+52%2025-102025-122026-022026-042026-062026-082026-10 2026-09-24 · Robinson Chandler sold $910.7K2026-09-24 · Robinson Chandler sold $847.8K2026-09-24 · Robinson Chandler sold $744.5K2026-10-01 · STARR CHRISTOPHER M sold $361.6K2025-12-18 · KLAUSNER ARTHUR J sold $312.5K2026-10-01 · STARR CHRISTOPHER M sold $234.1K2026-08-25 · Anderson Raymond sold $203.7K2026-08-26 · Tsuchimoto Kim R sold $122.8K2025-12-26 · Vu Quan Anh bought $104.9K2026-08-26 · Tsuchimoto Kim R sold $77.5K2026-08-25 · Anderson Raymond sold $76.4K2026-08-25 · Anderson Raymond sold $71.8K2026-08-26 · Tsuchimoto Kim R sold $68.0K2026-08-26 · Tsuchimoto Kim R sold $67.4K2026-08-26 · Tsuchimoto Kim R sold $67.2K2026-10-01 · STARR CHRISTOPHER M sold $63.7K2026-09-24 · Robinson Chandler sold $53.9K2026-08-26 · Tsuchimoto Kim R sold $52.8K2025-12-18 · KLAUSNER ARTHUR J sold $31.4K2026-08-26 · RIOUX PATRICE sold $1112026-10-01 · CHRISTOPHER STARR filed to sell $1.3M2026-09-24 · CHANDLER ROBINSON filed to sell $2.6M2026-08-26 · KIM TSUCHIMOTO filed to sell $906.5K2026-08-26 · PATRICE RIOUX filed to sell $1112026-08-25 · RAYMOND WILLIAM ANDERSON filed to sell $699.8K2026-07-07 · Arthur Klausner filed to sell $485.2K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MNPR: institutional holders (13F)

13F holdings, latest reported quarter
Jupiter Topco LLC
1,312,129 sh
$121.7M
RA CAPITAL MANAGEMENT, L.P.
667,207 sh
$61.8M
BlackRock, Inc.
348,819 sh
$32.3M
DEERFIELD MANAGEMENT COMPANY, L.P.
323,745 sh
$30.0M
Saturn V Capital Management LP
311,976 sh
$28.9M

Congress trades in MNPR

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MNPR planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
CHRISTOPHER STARR
Filed 2026-10-01
$1.3M
CHANDLER ROBINSON
Filed 2026-09-24
$2.6M
KIM TSUCHIMOTO
Filed 2026-08-26
$906.5K
PATRICE RIOUX
Filed 2026-08-26
$111
RAYMOND WILLIAM ANDERSON
Filed 2026-08-25
$699.8K

MNPR mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$563.4K position · as of 2026-07-31
1.2%
BNY Mellon Small/Mid Cap Growth Fund
$2.2M position · as of 2026-06-30
0.3%
Neuberger Small Cap Growth Fund
$1.6M position · as of 2026-05-31
0.2%
BNY Mellon Small Cap Multi-Strategy Fund
$122.7K position · as of 2026-05-31
0.1%
iShares Micro-Cap ETF
$1.4M position · as of 2026-06-30
0.1%
VANGUARD U.S. MOMENTUM FACTOR ETF
$1.3M position · as of 2026-05-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
2 active
2
Not applicable
0 active
1
Multi-phase
0 active
What changed recently
MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
2026-09-05 · Available → Temporarily Not Available
,
MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
2026-09-05 · Available → Temporarily Not Available
,
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
2026-09-04 · Completion moved 2026-04 → 2026-12
Phase 1
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
2026-09-04 · Recruiting → Active Not Recruiting
Phase 1
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
2026-09-04 · Completion moved 2026-12 → 2027-01
Phase 1
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
2026-09-04 · Recruiting → Active Not Recruiting
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Chandler D. Robinson
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$10.6M
$17.4M
$2.3M
+3739%
n/a
2024
$1.1M
$2.4M
$437.5K
+86%
n/a
2023
$1.8M
-$166.2K
$879.8K
-86%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.0M sold by insiders over 180 days, 64 funds added last quarter, $5.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MNPR financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-19.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-18.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-24.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0n/an/a
Operating income-$16.7M-$16.2M-$8.8M-$10.5M
Net income-$13.7M-$15.6M-$8.4M-$10.5M
Operating cash flow-$12.2M-$6.4M-$7.9M-$7.2M
Cash$61.8M$45.8M$7.3M$8.2M
Buybacks$35.0M$0n/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

MNPR Stock Sonar score 4/7 axes

Find similar shapesCompare

MNPR ranks highest on profitability (70th percentile) and institutional and government (53rd), and lowest on insider conviction (1st), among Pharma & Biotech peers.

Profitability
70
Inputs
  • Return on equity-19.5% · 72 pct, sector of 545
  • Return on assets-18.9% · 68 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-24.1% · 71 pct, sector of 576
Insider conviction
0
Inputs
  • Net Form 4 buying (codes P and S), 180dno Form 4 purchase or sale (code P or S) in 180 days
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
53
Inputs
  • Funds adding, latest quarter64 · 53 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
50
Inputs
  • Short interest, % of float+24.3% · 9 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+3.4% · 91 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MNPR filings, in plain words

Are Monopar Therapeutics insiders buying or selling MNPR?

In the 180 days to 2026-10-28, Monopar Therapeutics insiders were net sellers, a net $4.0M across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of MNPR?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $5.5M of stock; the latest, by CHRISTOPHER STARR, was filed 2026-10-01.

Read the full summary

In the 180 days to 2026-10-28, Monopar Therapeutics insiders were net sellers of MNPR, a net $4.0M across purchases and sales reported on Form 4 by 5 sellers. 100% of the 17 insider sales were made under a pre-arranged Rule 10b5-1 plan, so most selling was scheduled in advance. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $5.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies